Markers of the intensity of the viral infection (CXCL10, CCL22) were associated with response, suggesting that the downstream effects of viral replication contributed to antitumor immunity and potentiated the activity of pembrolizumab. The gene discussed is CXCL10; the disease is viral infectious disease.